<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>QUADRAMET- samarium sm-153 lexidronam pentasodium injection, solution </strong><br>Lantheus Medical Imaging, Inc.<br></p></div>
<h1>
<span class="Bold">QUADRAMET<span class="Sup">®</span>             Prescribing Information </span><br><br><span class="Bold">QUADRAMET</span><br><span class="Bold">(SAMARIUM SM 153 LEXIDRONAM         INJECTION)</span><br><br><span class="Bold">513145-1213 December 2013</span><br><span class="Bold"> <span class="Underline">                                                                                                                                                  </span></span><br><span class="Bold"><span class="Underline">                                 Therapeutic - For Intravenous             Administration                 </span></span>
</h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="LINK_f7bc8a74-9343-457c-a6cf-0c257d4e1ac6"></a><a name="section-1"></a><p></p>
<h1>DESCRIPTION</h1>
<p class="First">QUADRAMET<span class="Sup">®</span> is a therapeutic agent consisting of radioactive samarium and a tetraphosphonate chelator, ethylenediaminetetramethylenephosphonic acid (EDTMP). QUADRAMET<span class="Sup">®</span> is formulated as a sterile, non-pyrogenic, clear, colorless to light amber isotonic solution of samarium-153 lexidronam for intravenous administration. QUADRAMET<span class="Sup">®</span> does not contain a preservative.</p>
<p>Each milliliter contains 35 mg EDTMP•H<span class="Sub">2</span>O, 5.3 mg Ca [as Ca(OH)<span class="Sub">2</span>], 14.1 mg Na [as NaOH], equivalent to 44 mg Ca/Na EDTMP (anhydrous calc.), 5-46 µg samarium (specific activity of approximately 1.0-11.0 mCi/µg Sm), and 1850 ± 185 MBq (50 ± 5 mCi) of samarium-153 at calibration.</p>
<p>The structural formula of samarium lexidronam pentasodium is:</p>
<div class="Figure">
<a name="id218"></a><img alt="Structural formula of samarium lexidronam pentasodium." src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=61e84808-0999-4923-910c-2a480d5f971a&amp;name=quadramet-01.jpg">
</div>
<p>The ionic formula is <span class="Sup">153</span>Sm<span class="Sup">+3</span> [CH<span class="Sub">2</span>N(CH<span class="Sub">2</span>PO<span class="Sub">3</span><span class="Sup">-2</span>)<span class="Sub">2</span>]<span class="Sub">2</span> and the ionic formula weight is 581.1 daltons (pentasodium form, 696).</p>
<p>The pH of the solution is 7.0 to 8.5.</p>
<p>QUADRAMET<span class="Sup">®</span> is supplied frozen in single-dose glass vials containing 3 mL with 5550 MBq (150 mCi) of samarium-153 at calibration.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_60823e47-8ac0-44f2-9975-2f2cf9f2d7c2"></a><a name="section-1.1"></a><p></p>
<h2>Physical Characteristics</h2>
<p class="First">Samarium-153 is produced in high yield and purity by                                     neutron irradiation of isotopically enriched samarium Sm 152                                     oxide (<span class="Sup">152</span>Sm<span class="Sub">2</span>O<span class="Sub">3</span>). It emits both                                     medium-energy beta particles and a gamma photon, and has a                                     physical half-life of 46.3 hours (1.93 days). Samarium-153 has                                     average and maximum beta particle ranges in water of 0.5 mm and                                     3.0 mm, respectively. The primary radiation emissions of                                     samarium-153 are shown in Table 1.</p>
<a name="_RefID0EBBAC"></a><table>
<caption><span>TABLE 1 - SAMARIUM-153 PRINCIPAL RADIATION EMISSION                                         DATA </span></caption>
<col width="33%">
<col width="33%">
<col width="33%">
<tbody class="Headless">
<tr class="First">
<td class="Toprule" align="center"><p class="First"> </p></td>
<td class="Toprule" align="center"><p class="First"> <span class="Bold">Radiation</span><br><span class="Bold">Energy</span><br><span class="Bold">(</span><span class="Bold">keV</span><span class="Bold">)<span class="Sup">*</span></span></p></td>
<td class="Toprule" align="center"><p class="First"> <span class="Bold">Abundance</span></p></td>
</tr>
<tr>
<td align="center"><p class="First"> Beta</p></td>
<td align="center"><p class="First"> 640</p></td>
<td align="center"><p class="First"> 30%</p></td>
</tr>
<tr>
<td align="center"><p class="First"> Beta</p></td>
<td align="center"><p class="First"> 710</p></td>
<td align="center"><p class="First"> 50%</p></td>
</tr>
<tr>
<td align="center"><p class="First"> Beta</p></td>
<td align="center"><p class="First"> 810</p></td>
<td align="center"><p class="First"> 20%</p></td>
</tr>
<tr class="Last">
<td class="Botrule" align="center"><p class="First"> Gamma</p></td>
<td class="Botrule" align="center"><p class="First"> 103</p></td>
<td class="Botrule" align="center"><p class="First"> 29%</p></td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_cc06ad60-c2ea-4cb5-bca5-5f8b962560e4"></a><a name="section-1.2"></a><p></p>
<h2>External Radiation</h2>
<p class="First">The specific gamma-ray constant for samarium-153 is 0.46                                     R/mCi-hr at 1 cm (1.24x10<span class="Sup">-5</span> mSv/MBq- hr at 1 Meter).                                     The half-value thickness of lead (Pb) for samarium-153 is                                     approximately 0.10 mm. The use of 1 mm of lead will decrease the                                     external <span class="product-label-link" type="condition" conceptid="438630" conceptname="Exposure to radiation">radiation exposure</span> by a factor of approximately 1,000.                                         QUADRAMET<span class="Sup">®</span> should be stored in a                                     lead-shielded container and frozen until use.</p>
<p>Radioactive decay factors to be applied to the stated                                     value for radioactive concentration at calibration are given in                                     Table 2. All radioactivity is calibrated to the reference date                                     and time on the vial.</p>
<a name="_RefID0ESDAC"></a><table>
<caption><span>TABLE 2 - SAMARIUM-153 PHYSICAL DECAY CHART, HALF-LIFE                                         46.3 HOURS(1.93 DAYS) </span></caption>
<col width="25%">
<col width="25%">
<col width="25%">
<col width="25%">
<tbody class="Headless">
<tr class="First">
<td class="Toprule"><p class="First"> <span class="Bold">Time</span><br><span class="Bold">(hour)<span class="Sup">*</span></span></p></td>
<td class="Toprule"><p class="First"> <span class="Bold">Factor</span></p></td>
<td class="Toprule"><p class="First"> <span class="Bold">Time</span><br><span class="Bold">(hour)<span class="Sup">*</span></span></p></td>
<td class="Toprule"><p class="First"> <span class="Bold">Factor</span></p></td>
</tr>
<tr>
<td><p class="First"> -56.0</p></td>
<td><p class="First"> 2.31</p></td>
<td><p class="First"> +1.0</p></td>
<td><p class="First"> 0.99</p></td>
</tr>
<tr>
<td><p class="First"> -48.0</p></td>
<td><p class="First"> 2.05</p></td>
<td><p class="First"> +2.0</p></td>
<td><p class="First"> 0.97</p></td>
</tr>
<tr>
<td><p class="First"> -36.0</p></td>
<td><p class="First"> 1.71</p></td>
<td><p class="First"> +3.0</p></td>
<td><p class="First"> 0.96</p></td>
</tr>
<tr>
<td><p class="First"> -24.0</p></td>
<td><p class="First"> 1.43</p></td>
<td><p class="First"> +4.0</p></td>
<td><p class="First"> 0.94</p></td>
</tr>
<tr>
<td><p class="First"> -20.0</p></td>
<td><p class="First"> 1.35</p></td>
<td><p class="First"> +6.0</p></td>
<td><p class="First"> 0.91</p></td>
</tr>
<tr>
<td><p class="First"> -16.0</p></td>
<td><p class="First"> 1.27</p></td>
<td><p class="First"> +8.0</p></td>
<td><p class="First"> 0.89</p></td>
</tr>
<tr>
<td><p class="First"> -12.0</p></td>
<td><p class="First"> 1.20</p></td>
<td><p class="First"> +12.0</p></td>
<td><p class="First"> 0.84</p></td>
</tr>
<tr>
<td><p class="First"> -8.0</p></td>
<td><p class="First"> 1.13</p></td>
<td><p class="First"> +16.0</p></td>
<td><p class="First"> 0.80</p></td>
</tr>
<tr>
<td><p class="First"> -6.0</p></td>
<td><p class="First"> 1.09</p></td>
<td><p class="First"> +20.0</p></td>
<td><p class="First"> 0.74</p></td>
</tr>
<tr>
<td><p class="First"> -4.0</p></td>
<td><p class="First"> 1.06</p></td>
<td><p class="First"> +24.0</p></td>
<td><p class="First"> 0.70</p></td>
</tr>
<tr>
<td><p class="First"> -3.0</p></td>
<td><p class="First"> 1.05</p></td>
<td><p class="First"> +36.0</p></td>
<td><p class="First"> 0.58</p></td>
</tr>
<tr>
<td><p class="First"> -2.0</p></td>
<td><p class="First"> 1.03</p></td>
<td><p class="First"> +48.0</p></td>
<td><p class="First"> 0.49</p></td>
</tr>
<tr class="Last">
<td class="Botrule"><p class="First"> -1.0</p></td>
<td class="Botrule"><p class="First"> 1.02</p></td>
<td class="Botrule"><p class="First"> +56.0</p></td>
<td class="Botrule"><p class="First"> 0.43</p></td>
</tr>
</tbody>
</table>
<p> </p>
</div>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="LINK_61e3f130-ff31-458f-895c-41a1a3e8dfbd"></a><a name="section-2"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>
<p class="First">QUADRAMET<span class="Sup">®</span> (samarium Sm-153 EDTMP) has an                             affinity for bone and concentrates in areas of bone turnover in                             association with hydroxyapatite. In clinical studies employing planar                             imaging techniques, more QUADRAMET<span class="Sup">®</span> accumulates in                             osteoblastic lesions than in normal bone with a lesion-to-normal bone                             ratio of approximately 5. The mechanism of action of                                 QUADRAMET<span class="Sup">®</span> in relieving the <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> of bone                             <span class="product-label-link" type="condition" conceptid="432851" conceptname="Secondary malignant neoplastic disease">metastases</span> is not known.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_bb0a5a26-9a0e-410e-a226-e2ec2f8b5a83"></a><a name="section-2.1"></a><p></p>
<h2>Distribution</h2>
<p class="First">Human protein binding has not been studied; however, in                                     dog, rat and bovine studies, less than 0.5% of samarium-153                                     EDTMP is bound to protein. At physiologic pH, &gt;90% of the                                     complex is present as <span class="Sup">153</span>Sm[EDTMP]<span class="Sup">-5</span>, and                                     &lt;10% as <span class="Sup">153</span>SmH[EDTMP]<span class="Sup">-4</span>. The                                     octanol/ water partition coefficient is                                 &lt;10<span class="Sup">-5</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_84587fad-130f-45aa-8336-3620a853a843"></a><a name="section-2.2"></a><p></p>
<h2>Skeletal Uptake</h2>
<p class="First">The greater the number of metastatic lesions, the more                                     skeletal uptake of Sm-153 radioactivity. The relationship                                     between skeletal uptake and the size of the metastatic lesions                                     has not been studied. The total skeletal uptake of radioactivity                                     was 65.5%± 15.5% of the injected dose in 453 patients                                     with metastatic lesions from a variety of primary malignancies.                                     In a study of 22 patients with a wide range in the number of                                     metastatic sites, the % of the injected dose (% ID) taken up by                                     bone ranged from 56.3% in a patient with 5 metastatic lesions to                                     76.7% in a patient with 52 metastatic lesions. If the number of                                     metastatic lesions is fixed, over the range 0.1 to 3.0 mCi/kg,                                     the % ID taken up by bone is the same regardless of the                                 dose.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_31a9fe1a-6970-4ba5-a3cb-21186a79cf24"></a><a name="section-2.3"></a><p></p>
<h2>Metabolism</h2>
<p class="First">The complex formed by samarium and EDTMP is excreted as                                     an intact, single species that consists of one atom of the                                     Sm-153 and one molecule of the EDTMP, as shown by an analysis of                                     urine samples from patients (n=5) administered samarium Sm-153                                     EDTMP. Metabolic products of samarium Sm-153 EDTMP were not                                     detected in humans.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_91dc5f60-cde6-4ad5-819a-e229bc4cdf5f"></a><a name="section-2.4"></a><p></p>
<h2>Elimination</h2>
<p class="First">For QUADRAMET<span class="Sup">®</span>, calculations of the %                                     ID detected in the whole body, urine and blood were corrected                                     for radionuclide decay. The clearance of activity through the                                     urine is expressed as the cumulated activity excreted. The whole                                     body retention is the simple reciprocal of the cumulated urine                                     activity. (See <a href="#_Ref">Skeletal                                     Uptake</a> Section).</p>
<p>Blood: Clearance of radioactivity from the blood                                     demonstrated biexponential kinetics after intravenous injection                                     in 19 patients (10 men, 9 women) with a variety of primary                                     cancers that were metastatic to bone. Over the first 30 minutes,                                     the radioactivity (mean ± SD) in the blood decreased to                                     15% (±8%) of the injected dose with a t 1/2 of 5.5 min                                     (±1.1 min). After 30 minutes, the radioactivity cleared                                     from the blood more slowly with a t1/2 of 65.4 min (±                                     9.6 min). Less than 1% of the dose injected remained in the                                     blood 5 hr after injection.</p>
<p>Urine: Samarium Sm-153 EDTMP radioactivity was excreted                                     in the urine after intravenous injection. During the first 6                                     hours, 34.5% (±15.5%) was excreted. Overall, the                                     greater the number of metastatic lesions, the less radioactivity                                     was excreted.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_7e16aed1-8b01-4486-9db4-75c9f6ea591d"></a><a name="section-2.5"></a><p></p>
<h2>Gender Differences</h2>
<p class="First">Gender did not affect the samarium Sm-153 EDTMP blood                                     pharmacokinetics, the cumulative % of radioactivity excreted in                                     urine, or the % radioactivity retained in the skeleton when the                                     number of metastatic lesions is taken into account.</p>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="LINK_57dc6471-c26b-40c9-b606-227e738bae3c"></a><a name="section-2.6"></a><p></p>
<h2>Special Populations</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_beb265f2-f9aa-4625-a1cf-1888e9667818"></a><a name="section-2.6.1"></a><p></p>
<p class="First">Elderly: The pharmacokinetics of samarium Sm-153                                             EDTMP did not change with age as seen from comparison of                                             values from people in the age range of 22 to 64 compared                                             to the range 65 to 86 years.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_d99bf605-1f90-47f4-a033-7a12221fc067"></a><a name="section-2.6.2"></a><p></p>
<p class="First"><span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">Hepatic Insufficiency</span>: Samarium Sm-153 EDTMP                                             scintiscans in 5 patients with metastatic bone disease                                             did not reveal accumulation of activity in the liver or                                             the intestine; this suggests that hepatobiliary                                             excretion did not occur.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_87d141da-fa76-4a03-b9bf-68386dc567f0"></a><a name="section-2.6.3"></a><p></p>
<p class="First"><span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">Renal Insufficiency</span>: Patients with renal                                             insufficiency have not been studied.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_9bf41b0e-9057-4a21-b1fb-60ca69607b00"></a><a name="section-2.7"></a><p></p>
<h2>Drug/Drug Interaction</h2>
<p class="First">Drug-drug interaction studies have not been                                 studied.</p>
</div>
<div class="Section" data-sectionCode="43681-6">
<a name="LINK_fcc0c4f7-a4e8-440d-9570-53cd2b64ea85"></a><a name="section-2.8"></a><p></p>
<h2>Pharmacodynamics</h2>
<p class="First">The beta particle of <span class="Sup">153</span>Sm-EDTMP travels a                                     maximum of 3.0 mm in soft tissue and 1.7 mm in bone. In clinical                                     trials of 78 patients with metastatic bone lesions who had 13                                     specific bone scan sites evaluated, the presence or absence of                                         <span class="Sup">153</span>Sm-EDTMP uptake is similar to the presence or                                     absence of <span class="Sup">99m</span>Tc diphosphonate uptake (range 67 to                                     96% agreement depending upon the blinded reader and the site of                                     the body). Whether the amount of <span class="Sup">153</span>Sm-EDTMP uptake                                     varies with the size of the lesion or to the presence of                                     osteolytic components has not been studied. The clinical benefit                                     of Sm-153-EDTMP in patients with osteolytic lesions is not                                     known. The relationship of different tumor cell types to                                     clinical response has not been studied.</p>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="LINK_3eb6acd2-10b4-41df-b177-4d9236ef0581"></a><a name="section-3"></a><p></p>
<h1>CLINICAL TRIALS</h1>
<p class="First">Overall QUADRAMET<span class="Sup">®</span> was evaluated in 580                             patients (see <a href="#_Ref">Adverse                             Events</a> Section for demographic description). Of these                             patients, 270 (244 men, 26 women) were studied in two randomized,                             blinded, placebo controlled clinical trials. These patients had a mean                             age of 67, and a range 22 to 87 years. Eligible patients had painful                             metastatic bone lesions that had failed other treatments, had at least a                             6 month expected survival and had a positive radionuclide bone scan.                             Routine x-rays to evaluate the metastatic lesions were not part of the                             protocol.</p>
<p>In study A, 118 patients were randomized to receive 0.5 mCi/kg                                 QUADRAMET<span class="Sup">®</span>, 1.0 mCi/kg                             QUADRAMET<span class="Sup">®</span>, or a placebo intravenous injection. In                             study B, 152 patients were randomized to receive either 1.0 mCi/kg                                 QUADRAMET<span class="Sup">®</span> or a placebo intravenous injection.                             Both studies were double blind over a 4 week period. Patients scored                             their daily <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> intensity on a visual analogue scale rated from 0 (no                             or low <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>) to 10 (excruciating <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>). The area under the <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> curve                             (AUPC) was obtained by integrating the daily <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> scores by week. Opioid                             analgesic use was recorded daily and averaged over each week and                             expressed in oral morphine milligram equivalents.</p>
<p>Of the 270 patients studied, 232 (86%) had prostate cancer and 38                             (14%) had other primary cancers. In study A, 80 (68%) of the patients                             had prostate cancer and 38 (32%) had a variety of other primary tumors.                             In study B, all (100%) patients had prostate cancer.</p>
<p>The results of the patients' AUPC scores are shown in                             Table 3. In both trials for each of the 4 weeks of study, the mean AUPC                             scores decreased in patients who received QUADRAMET<span class="Sup">®</span>                             (1.0 mCi/kg). In study A, <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> (the AUPC) decrease from baseline was                             significantly different in QUADRAMET<span class="Sup">®</span> 1.0 mCi/kg and                             placebo groups at weeks 3 and 4. In study B, <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> (the AUPC) decrease                             from baseline was significantly different in                             QUADRAMET<span class="Sup">®</span> 1.0 mCi/kg and placebo groups at weeks 2,                             3 and 4.</p>
<a name="_RefID0EIOAC"></a><table>
<caption><span>Table 3: COMPARISON OF WEEKLY <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">PAIN</span> SCORES (a)AFTER                                     QUADRAMET<span class="Sup">®</span> 1.0mCi/kg or PLACEBO IV [Intent                                 to Treat]</span></caption>
<col width="20%">
<col width="20%">
<col width="20%">
<col width="20%">
<col width="20%">
<tbody class="Headless">
<tr class="First">
<td class="Toprule"><p class="First"> </p></td>
<td class="Toprule" align="center" colspan="2"><p class="First"> STUDY A (n = 73) (b)</p></td>
<td class="Toprule" align="center" colspan="2"><p class="First"> STUDY B (n = 150) (c)</p></td>
</tr>
<tr>
<td><p class="First"> WEEK</p></td>
<td>
<p class="First"> </p>
<p>    Placebo</p>
<p>    N=36</p>
</td>
<td>
<p class="First"> </p>
<p>    1.0                                             mCi/kg</p>
<p>    N=37</p>
</td>
<td>
<p class="First"> </p>
<p>    Placebo</p>
<p>    N=50</p>
</td>
<td>
<p class="First"> </p>
<p>    1.0                                             mCi/kg</p>
<p>    N=100</p>
</td>
</tr>
<tr>
<td><p class="First"> Baseline</p></td>
<td><p class="First">     26.5 (11.8)</p></td>
<td><p class="First">     28.7 (12.3)</p></td>
<td><p class="First">     28.5 (14.1)</p></td>
<td><p class="First">     28.1 (12.9)</p></td>
</tr>
<tr>
<td><p class="First"> 1</p></td>
<td><p class="First">     26.1 (10.3)</p></td>
<td><p class="First">     27.6 (14.1)</p></td>
<td><p class="First">     27.9 (14.6)</p></td>
<td><p class="First">     25.8 (13.1)</p></td>
</tr>
<tr>
<td><p class="First"> 2</p></td>
<td><p class="First">     24.4 (10.4)</p></td>
<td><p class="First">     23.8 (13.7)</p></td>
<td><p class="First">     28.1 (15.4)</p></td>
<td><p class="First">     20.6 (13.9)*</p></td>
</tr>
<tr>
<td><p class="First"> 3</p></td>
<td><p class="First">     24.3 (11.0)</p></td>
<td><p class="First">     20.5 (11.5)*</p></td>
<td><p class="First">     25.8 (16.1)</p></td>
<td><p class="First">     20.1 (13.3)*</p></td>
</tr>
<tr class="Last">
<td class="Botrule"><p class="First"> 4</p></td>
<td class="Botrule"><p class="First">     24.7 (12.1)</p></td>
<td class="Botrule"><p class="First">     18.8 (10.8)*</p></td>
<td class="Botrule"><p class="First">     24.7 (15.3)</p></td>
<td class="Botrule"><p class="First">     19.9 (13.7)*</p></td>
</tr>
</tbody>
</table>
<dl>
<dt>•</dt>
<dd>(a) Area Under the <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">Pain</span> Curve (SD).</dd>
<dt> </dt>
<dd>(b) Excludes 5 patients with missing baseline or extreme                                     values; and all 40 patients who received 0.5 mCi                                         QUADRAMET<span class="Sup">®</span>.                                     QUADRAMET<span class="Sup">®</span> 0.5 mCi/kg can not be                                     distinguished from placebo. </dd>
<dt> </dt>
<dd>(c) Excludes 2 patients with missing baseline values.                                 </dd>
</dl>
<dl>
<dt>•</dt>
<dd>(*) Statistically significant difference in change from baseline                                 in comparison to placebo.</dd>
</dl>
<p>In the two clinical trials, the patient use of analgesics                             differed. In Study A, the patients did not receive specific instructions                             on analgesic reduction. In Study B, patients were encouraged to adjust                             their <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> medication as needed. As shown in Table 4, the morphine                             equivalent analgesic use in study A generally increased from baseline in                             both the QUADRAMET<span class="Sup">®</span> and placebo treatment groups;                             however, the difference between the QUADRAMET<span class="Sup">®</span> and                             placebo group change from baseline is not statistically significant. In                             study B, the placebo treated patients increased their use of opioid                             analgesics, while the QUADRAMET<span class="Sup">®</span> treated patients                             decreased their use of opioid analgesics.</p>
<a name="_RefID0ECBAE"></a><table>
<caption><span>Table 4: COMPARISON OF WEEKLY MEAN ANALGESIC USE (a) BETWEEN                                     QUADRAMET<span class="Sup">®</span> 1.0 mCi/kg AND PLACEBO GROUPS                                 [Intent to Treat]</span></caption>
<col width="20%">
<col width="20%">
<col width="20%">
<col width="20%">
<col width="20%">
<tbody class="Headless">
<tr class="First">
<td class="Toprule"><p class="First"> </p></td>
<td class="Toprule" align="center" colspan="2"><p class="First"> STUDY A (n = 73) (b)</p></td>
<td class="Toprule" align="center" colspan="2"><p class="First"> STUDY B (n = 150) (c)</p></td>
</tr>
<tr>
<td><p class="First"> WEEK</p></td>
<td>
<p class="First"> </p>
<p>    Placebo </p>
<p>    N=36</p>
</td>
<td>
<p class="First"> </p>
<p>    1.0                                             mCi/kg</p>
<p>    N=37</p>
</td>
<td>
<p class="First"> </p>
<p>    Placebo</p>
<p>    N=50</p>
</td>
<td>
<p class="First"> </p>
<p>    1.0                                             mCi/kg</p>
<p>    N=100</p>
</td>
</tr>
<tr>
<td><p class="First"> Baseline</p></td>
<td><p class="First">     93.5 (154.0)(a)</p></td>
<td><p class="First">     127.1 (189.9)</p></td>
<td><p class="First">     78.4 (83.1)</p></td>
<td><p class="First">     96.5 (166.6)</p></td>
</tr>
<tr>
<td><p class="First"> 1</p></td>
<td><p class="First">     106.8 (173.8)</p></td>
<td><p class="First">     125.7 (192.6)</p></td>
<td><p class="First">     84.5 (91.1)</p></td>
<td><p class="First">     93.5 (165.5)</p></td>
</tr>
<tr>
<td><p class="First"> 2</p></td>
<td><p class="First">     127.1 (238.4)</p></td>
<td><p class="First">     144.8 (276.7)</p></td>
<td><p class="First">     85.6 (90.9)</p></td>
<td><p class="First">     82.9 (122.9)</p></td>
</tr>
<tr>
<td><p class="First"> 3</p></td>
<td><p class="First">     133.9 (254.0)</p></td>
<td><p class="First">     146.6 (278.2)</p></td>
<td><p class="First">     100.1 (119.4)</p></td>
<td><p class="First">     79.6 (131.2)*</p></td>
</tr>
<tr class="Last">
<td class="Botrule"><p class="First"> 4</p></td>
<td class="Botrule"><p class="First">     135.6 (222.0)</p></td>
<td class="Botrule"><p class="First">     135.1 (274.0)</p></td>
<td class="Botrule"><p class="First">     106.3 (161.0)</p></td>
<td class="Botrule"><p class="First">     76.8 (132.3)*</p></td>
</tr>
</tbody>
</table>
<dl>
<dt>•</dt>
<dd>(a) Mean Analgesic Use (SD) is in morphine equivalent units; 0 =                                 none.</dd>
<dt>•</dt>
<dd>(b) Excludes 5 patients with missing baseline or with extreme                                 values; and all 40 patients who received 0.5 mCi                                     QUADRAMET<span class="Sup">®</span>. QUADRAMET<span class="Sup">®</span>                                 0.5 mCi/kg can not be distinguished from placebo.</dd>
<dt> </dt>
<dd>(c) Excludes 2 patients with missing baseline                                 values.</dd>
<dt> </dt>
<dd>(*) Statistically significant difference in change from                                     baseline in comparison to placebo.</dd>
</dl>
<p>In both studies, the numbers of patients who experienced any                             decrease in AUPC score without any increase in analgesic use at weeks 3                             and 4 were also evaluated. In study A, this occurred in 20/37 (54%) of                             the patients who received QUADRAMET<span class="Sup">®</span> 1.0 mCi/kg and                             9/36 (25%) of the placebo treated patients. In study B, this occurred in                             48/100 (48%) of the QUADRAMET<span class="Sup">®</span> treated patients and                             11/51 (22%) of the placebo treated patients.</p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="LINK_d78d4773-aea6-4e97-81a6-89a230833c2e"></a><a name="section-4"></a><p></p>
<h1>INDICATIONS</h1>
<p class="First">QUADRAMET<span class="Sup">®</span> is indicated for relief of <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> in                             patients with confirmed osteoblastic metastatic bone lesions that                             enhance on radionuclide bone scan.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="LINK_afd36f56-76ee-4319-b151-d01544a2af84"></a><a name="section-5"></a><p></p>
<h1>CONTRAINDICATIONS</h1>
<p class="First">QUADRAMET<span class="Sup">®</span> is contraindicated in patients who                             have known <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to EDTMP or similar phosphonate                         compounds.</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="LINK_ec5b042e-73da-4c06-bcd8-6a2cf74a11a3"></a><a name="section-6"></a><p></p>
<h1>WARNINGS</h1>
<p class="First">QUADRAMET<span class="Sup">®</span> causes bone marrow suppression. In                             clinical trials, white blood cell counts and platelet counts decreased                             to a nadir of approximately 40% to 50% of baseline in 123 (95%) of                             patients within 3 to 5 weeks after QUADRAMET<span class="Sup">®</span>, and                             tended to return to pretreatment levels by 8 weeks. The grade of marrow                             toxicity is shown in Table 5 below.</p>
<a name="_RefID0EOFAE"></a><table>
<caption><span>Table 5: NUMBER AND PERCENT OF PATIENTS WHO EXPERIENCED MARROW                                 TOXICITY IN CLINICAL TRIALS OF QUADRAMET<span class="Sup">®</span></span></caption>
<col width="14%">
<col width="14%">
<col width="14%">
<col width="14%">
<col width="14%">
<col width="14%">
<col width="14%">
<tbody class="Headless">
<tr class="First">
<td class="Toprule"><p class="First"> </p></td>
<td class="Toprule" align="center" colspan="2"><p class="First"> <span class="Bold">Hemoglobin</span></p></td>
<td class="Toprule" align="center" colspan="2"><p class="First"> <span class="Bold">Leucocytes</span></p></td>
<td class="Toprule" align="center" colspan="2"><p class="First"> <span class="Bold">Platelets</span></p></td>
</tr>
<tr>
<td><p class="First"> <span class="Bold">Toxicity Grade*</span></p></td>
<td>
<p class="First"> </p>
<p>    Placebo</p>
<p>    N=85</p>
</td>
<td>
<p class="First"> </p>
<p>    1.0                                             mCi/kg</p>
<p>    N=185</p>
</td>
<td>
<p class="First"> </p>
<p>    Placebo</p>
<p>    N=85</p>
</td>
<td>
<p class="First"> </p>
<p>    1.0                                             mCi/kg</p>
<p>    N=184</p>
</td>
<td>
<p class="First"> </p>
<p>    Placebo</p>
<p>    N=85</p>
</td>
<td>
<p class="First"> </p>
<p>    1.0                                             mCi/kg</p>
<p>    N=185</p>
</td>
</tr>
<tr>
<td><p class="First"> 0-2</p></td>
<td><p class="First">     78 (92%)</p></td>
<td><p class="First">     162 (88%)</p></td>
<td><p class="First">     85 (100%)</p></td>
<td><p class="First">     169 (92%)</p></td>
<td><p class="First">     85 (100%)</p></td>
<td><p class="First">     173 (94%)</p></td>
</tr>
<tr>
<td><p class="First"> 3</p></td>
<td><p class="First">     6 (7%)</p></td>
<td><p class="First">     20 (11%)</p></td>
<td><p class="First">     0 (0%)</p></td>
<td><p class="First">     15 (8%)</p></td>
<td><p class="First">     0 (0%)</p></td>
<td><p class="First">     10 (5%)</p></td>
</tr>
<tr class="Last">
<td class="Botrule"><p class="First"> 4</p></td>
<td class="Botrule"><p class="First">     1 (1%)</p></td>
<td class="Botrule"><p class="First">     3 (2%)</p></td>
<td class="Botrule"><p class="First">     0 (0%)</p></td>
<td class="Botrule"><p class="First">     0 (0%)</p></td>
<td class="Botrule"><p class="First">     0 (0%)</p></td>
<td class="Botrule"><p class="First">     2 (1%)</p></td>
</tr>
</tbody>
</table>
<dl>
<dt>•</dt>
<dd>* Toxicity Grade based upon National Cancer Institute Criteria;                                 normal levels are Hemoglobin ≥10g/dL, Leucocyte                                 ≥4.0 x 10<span class="Sup">3</span>µL, and Platelets                                 ≥150,000/µL.</dd>
</dl>
<p>Before QUADRAMET<span class="Sup">®</span> is administered,                             consideration should be given to the patient's current                             clinical and hematologic status and bone marrow response history to                             treatment with myelotoxic agents. Metastatic prostate and other cancers                             can be associated with <span class="product-label-link" type="condition" conceptid="436093" conceptname="Disseminated intravascular coagulation">disseminated intravascular coagulation</span> (DIC);                             caution should be exercised in treating cancer patients whose platelet                             counts are <span class="product-label-link" type="condition" conceptid="436583" conceptname="Fall">falling</span> or who have other clinical or laboratory findings                             suggesting DIC. Because of the unknown potential for additive effects on                             bone marrow, QUADRAMET<span class="Sup">®</span> should not be given                             concurrently with chemotherapy or external beam radiation therapy unless                             the clinical benefits outweigh the risks. Use of                                 QUADRAMET<span class="Sup">®</span> in patients with evidence of                             compromised bone marrow reserve from previous therapy or disease                             involvement is not recommended unless the potential benefits of the                             treatment outweigh the risks. Blood counts should be monitored weekly                             for at least 8 weeks, or until recovery of adequate bone marrow                             function.</p>
<div class="Section" data-sectionCode="42228-7">
<a name="LINK_675b54a2-86ab-461b-baf4-06d88766e491"></a><a name="section-6.1"></a><p></p>
<h2>Pregnancy</h2>
<p class="First">As with other radiopharmaceutical drugs,                                         QUADRAMET<span class="Sup">®</span> can cause fetal harm when                                     administered to a pregnant woman. Adequate and well controlled                                     studies have not been conducted in animals or pregnant women.                                     Women of child-bearing age should have a <span class="product-label-link" type="condition" conceptid="4094448" conceptname="Pregnancy test negative">negative pregnancy test</span>                                     before administration of QUADRAMET<span class="Sup">®</span>. If this                                     drug is used during pregnancy, or if a patient becomes pregnant                                     after taking this drug, the patient should be apprised of the                                     potential hazard to the fetus. Women of child-bearing potential                                     should be advised to avoid becoming pregnant soon after                                     receiving QUADRAMET<span class="Sup">®</span>. Men and women patients                                     should be advised to use an effective method of contraception                                     after the administration of                                 QUADRAMET<span class="Sup">®</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="LINK_e807d5b1-35c5-49ba-897d-9e1042bbef54"></a><a name="section-7"></a><p></p>
<h1>PRECAUTIONS</h1>
<p class="First">EDTMP is a chelating agent. Although the chelating effects have                             not been evaluated thoroughly in humans, dogs that received                             non-radioactive samarium EDTMP (6 times the human dose based on body                             weight, 3 times based on surface area) developed a variety of                             electrocardiographic (ECG) changes (with or without the presence of                             <span class="product-label-link" type="condition" conceptid="435510" conceptname="Hypocalcemia">hypocalcemia</span>). The causal relationship between the <span class="product-label-link" type="condition" conceptid="435510" conceptname="Hypocalcemia">hypocalcemia</span> and ECG                             changes has not been studied. Whether QUADRAMET<span class="Sup">®</span>                             causes electrocardiographic changes or <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">arrhythmias</span> in humans has not                             been studied. Caution and appropriate monitoring should be given when                             administering QUADRAMET<span class="Sup">®</span> to patients (See <a href="#_Ref">Laboratory                             Tests</a>).</p>
<p>Because concomitant hydration is recommended to promote the                             urinary excretion of QUADRAMET<span class="Sup">®</span>, appropriate                             monitoring and consideration of additional supportive treatment should                             be used in patients with a history of <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span> or renal                             insufficiency.</p>
<p>This drug should be used with caution in patients with                             compromised bone marrow reserves. See <a href="#_Ref">Warnings</a>.</p>
<p>Skeletal: <span class="product-label-link" type="condition" conceptid="4322945" conceptname="Spinal cord compression">Spinal cord compression</span> frequently occurs in patients                             with known <span class="product-label-link" type="condition" conceptid="432851" conceptname="Secondary malignant neoplastic disease">metastases</span> to the cervical, thoracic or lumbar spine. In                             clinical studies of QUADRAMET<span class="Sup">®</span>, spinal cord                             compression was reported in 7% of patients who received placebo and in                             8.3% of patients who received 1.0 mCi/kg QUADRAMET<span class="Sup">®</span>.                                 QUADRAMET<span class="Sup">®</span> is not indicated for treatment of                             <span class="product-label-link" type="condition" conceptid="4322945" conceptname="Spinal cord compression">spinal cord compression</span>. QUADRAMET<span class="Sup">®</span> administration                             for <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> relief of metastatic bone cancer does not prevent the                             development of <span class="product-label-link" type="condition" conceptid="4322945" conceptname="Spinal cord compression">spinal cord compression</span>. When there is a clinical                             suspicion of <span class="product-label-link" type="condition" conceptid="4322945" conceptname="Spinal cord compression">spinal cord compression</span>, appropriate diagnostic and                             therapeutic measures must be taken immediately to avoid permanent                             <span class="product-label-link" type="condition" conceptid="4052648" conceptname="Disability">disability</span>.</p>
<p>Radiopharmaceutical agents should be used only by physicians who                             are qualified by training and experience in the safe use and handling of                             radionuclides and whose experience and training have been approved by                             the appropriate government agency authorized to license the use of                             radionuclides.</p>
<p>QUADRAMET<span class="Sup">®</span>, like other radioactive drugs,                             must be handled with care, and appropriate safety measures must be taken                             to minimize <span class="product-label-link" type="condition" conceptid="438630" conceptname="Exposure to radiation">radiation exposure</span> of clinical personnel and others in the                             patient environment.</p>
<p>Special precautions, such as bladder catheterization, should be                             taken with <span class="product-label-link" type="condition" conceptid="444035" conceptname="Incontinence">incontinent</span> patients to minimize the risk of radioactive                             contamination of clothing, bed linen, and the patient's environment.                             Urinary excretion of radioactivity occurs over about 12 hours (with 35%                             occurring during the first 6 hours). Studies have not been done on the                             use of QUADRAMET<span class="Sup">®</span> in patients with renal                         impairment.</p>
<div class="Section" data-sectionCode="34076-0">
<a name="LINK_6832db37-7572-4508-96db-abe5ee5af1cc"></a><a name="section-7.1"></a><p></p>
<h2>INFORMATION FOR PATIENTS</h2>
<p class="First">Patients who receive QUADRAMET<span class="Sup">®</span>                                     should be advised that for several hours following                                     administration, radioactivity will be present in excreted urine.                                     To help protect themselves and others in their environment,                                     precautions need to be taken for 12 hours following                                     administration. Whenever possible, a toilet should be used,                                     rather than a urinal, and the toilet should be <span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">flushed</span> several                                     times after each use. Spilled urine should be cleaned up                                     completely and patients should wash their hands thoroughly. If                                     blood or urine gets onto clothing, the clothing should be washed                                     separately, or stored for 1-2 weeks to allow for decay of the                                     Sm-153. </p>
<p>Some patients have reported a transient increase in bone                                     <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> shortly after injection (flare reaction). This is usually                                     mild and self-limiting and occurs within 72 hours of injection.                                     Such reactions are usually responsive to analgesics.</p>
<p>Patients who respond to QUADRAMET<span class="Sup">®</span>                                     might begin to notice the onset of <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> relief one week after                                         QUADRAMET<span class="Sup">®</span>. Maximal <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> relief                                     generally occurs at 3-4 weeks after injection of                                         QUADRAMET<span class="Sup">®</span>. Patients who experience a                                     reduction in <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> may be encouraged to decrease their use of                                     opioid analgesics.</p>
</div>
<div class="Section" data-sectionCode="34075-2">
<a name="LINK_28499b2d-7c82-474a-a74c-e7ecbb7549b1"></a><a name="section-7.2"></a><p></p>
<h2>LABORATORY TESTS</h2>
<p class="First">Because of the potential for bone marrow suppression,                                     beginning 2 weeks after QUADRAMET<span class="Sup">®</span>                                     administration, blood counts should be monitored weekly for at                                     least 8 weeks, or until recovery of adequate bone marrow                                     function.</p>
<p>In a subset of 31 patients who had serum calcium                                     monitored during the first 2 hours after                                         QUADRAMET<span class="Sup">®</span> infusion, a clear pattern of                                     calcium change was not identified. However, 10 (32%) patients                                     had at least one serum calcium level that was below normal (7.16                                     to 8.28). The extent to which samarium-153-EDTMP is related to                                     this <span class="product-label-link" type="condition" conceptid="435510" conceptname="Hypocalcemia">hypocalcemia</span> is not known. Caution should be exercised when                                     administering QUADRAMET<span class="Sup">®</span> to patients at risk                                     for developing <span class="product-label-link" type="condition" conceptid="435510" conceptname="Hypocalcemia">hypocalcemia</span>.</p>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="LINK_0369ebcc-dc3b-4012-87fe-31c5f69c2aed"></a><a name="section-7.3"></a><p></p>
<h2>DRUG INTERACTIONS</h2>
<p class="First">The potential for additive bone marrow toxicity of                                         QUADRAMET<span class="Sup">®</span> with chemotherapy or external                                     beam radiation has not been studied.                                     QUADRAMET<span class="Sup">®</span> should not be given concurrently                                     with chemotherapy or external beam radiation therapy unless the                                     benefit outweighs the risks. QUADRAMET<span class="Sup">®</span>                                     should not be given after either of these treatments until there                                     has been time for adequate marrow recovery.                                         (See <a href="#_Ref">Warnings</a> Section).</p>
</div>
<div class="Section" data-sectionCode="34083-6">
<a name="LINK_35a0a1d4-9467-40ff-a621-bae49f70ea8c"></a><a name="section-7.4"></a><p></p>
<h2>CARCINOGENESIS, MUTAGENESIS,                                 IMPAIRMENT OF FERTILITY</h2>
<p class="First">Carcinogenesis in humans given EDTMP, in                                         QUADRAMET<span class="Sup">®</span>, is not likely. <span class="product-label-link" type="condition" conceptid="4070783" conceptname="Osteosarcoma">Osteosarcomas</span>                                     occurred in a 2-year toxicity/carcinogenicity study of EDTMP                                     administered by gastric intubation to Sprague-Dawley rats, in                                     male rats at 50 mg/kg/day and in male and female rats at 150                                     mg/kg/day (the dosage was increased to 333 mg/kg/day on day 329                                     of treatment). <span class="product-label-link" type="condition" conceptid="4070783" conceptname="Osteosarcoma">Osteosarcomas</span> were not reported in a published                                     chronic dietary study of up to 130 weeks of EDTMP in Fisher 344                                     rats, at dietary doses up to 100 mg/kg/day (not the maximum                                     tolerated dose). However, at study termination in female Fisher                                     344 rats, this dose was associated with statistically                                     significantly higher rate of pancreatic islet-cell <span class="product-label-link" type="condition" conceptid="4106411" conceptname="Adenofibroma">adenomas</span> and                                     carcinomas.</p>
<p>The results of the following genotoxicity assays with                                     non-radioactive samarium- EDTMP were negative: <span class="product-label-link" type="condition" conceptid="4235289" conceptname="Salmonellosis">Salmonella</span>                                     reverse mutation (AMES) assay, unscheduled DNA synthesis in rat                                     liver primary cell culture, chromosomal aberration assay in rat                                     <span class="product-label-link" type="condition" conceptid="4254663" conceptname="Lymphocyte count">lymphocytes</span>, CHO/HGPRT forward mutation assay, and mouse bone                                     marrow micronucleus test.</p>
<p>Studies have not been performed to assess the effect of                                         QUADRAMET<span class="Sup">®</span> on fertility.</p>
</div>
<div class="Section" data-sectionCode="42228-7">
<a name="LINK_efc61178-b15a-46d1-9eb4-9f906716d184"></a><a name="section-7.5"></a><p></p>
<h2>PREGNANCY</h2>
<p class="First">Pregnancy Category D. See <a href="#_Ref">Warnings</a> Section.</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="LINK_15d46f60-a8d1-485d-9e80-22cd16659dac"></a><a name="section-7.6"></a><p></p>
<h2>NURSING MOTHERS</h2>
<p class="First">It is not known whether QUADRAMET<span class="Sup">®</span> is                                     excreted in human milk. Because of the potential for serious                                     adverse reactions in nursing infants from                                         QUADRAMET<span class="Sup">®</span>, a decision should be made                                     whether to continue nursing or to administer the drug. If                                         QUADRAMET<span class="Sup">®</span> is administered, formula                                     feedings should be substituted for breast feedings.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="LINK_70373be5-21ee-46ec-8fc9-c05870137785"></a><a name="section-7.7"></a><p></p>
<h2>PEDIATRIC USE</h2>
<p class="First">Safety and effectiveness in pediatric patients below the                                     age of 16 years have not been established.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="LINK_d621d1ae-0e41-4843-8c83-9ccc8b9eb3bf"></a><a name="section-8"></a><p></p>
<h1>ADVERSE EVENTS</h1>
<p class="First">Adverse events were evaluated in a total of 580 patients who                             received QUADRAMET<span class="Sup">®</span> in clinical trials. Of the 580                             patients, there were 472 men and 108 women with a mean age of 66 (range                             20 to 87).</p>
<p>Of these patients, 472 (81%) had at least one adverse event. In a                             subgroup of 399 patients who received QUADRAMET<span class="Sup">®</span> 1.0                             mCi/kg, there were 23 <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">deaths</span> and 46 serious adverse events. The <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">deaths</span>                             occurred an average of 67 days (9 to 130) after                             QUADRAMET<span class="Sup">®</span>. Serious events occurred an average of 46                             days (1 - 118) after QUADRAMET<span class="Sup">®</span>. Although most of                             the patient <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">deaths</span> and serious adverse events appear to be related to                             the underlying disease, the relationship of end stage disease, marrow                             invasion by cancer cells, previous myelotoxic treatment and                                 QUADRAMET<span class="Sup">®</span> toxicity can not be easily                             distinguished. In clinical studies, two patients with rapidly                             progressive prostate cancer developed <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span> and died 4 weeks                             after receiving QUADRAMET<span class="Sup">®</span>. One of the patients                             showed evidence of <span class="product-label-link" type="condition" conceptid="436093" conceptname="Disseminated intravascular coagulation">disseminated intravascular coagulation</span> (DIC); the                             other patient experienced a fatal <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">cerebrovascular accident</span>, with a                             suspicion of DIC. The relationship of the DIC to the bone marrow                             suppressive effect of Samarium is not known. Marrow toxicity occurred in                             277 (48%) patients (See <a href="#_Ref">Warnings</a>                             section).</p>
<p>In controlled studies, 7% of patients receiving 1.0 mCi/kg                                 QUADRAMET<span class="Sup">®</span> (as compared to 6% of patients                             receiving placebo) reported a transient increase in <span class="product-label-link" type="condition" conceptid="4129418" conceptname="Bone pain">bone pain</span> shortly                             after injection (flare reaction). This was usually mild, self-limiting,                             and responded to analgesics.</p>
<p>The most common adverse events observed in controlled clinical                             studies of QUADRAMET<span class="Sup">®</span>, are given in Table                             6.    </p>
<a name="_RefID0EYQAE"></a><table>
<caption><span>TABLE 6 SELECTED ADVERSE EVENTS REPORTED                                 IN ≥ 1.0 % OF PEOPLE WHO RECEIVED                                     QUADRAMET<span class="Sup">®</span> OR PLACEBO IN CONTROLLED CLINICAL                                 TRIALS </span></caption>
<col width="33%">
<col width="33%">
<col width="33%">
<tbody class="Headless">
<tr class="First">
<td class="Toprule">
<p class="First"> </p>
<p>ADVERSE EVENT</p>
</td>
<td class="Toprule">
<p class="First"> </p>
<p>    Placebo<br><br>    N                                             = 90</p>
</td>
<td class="Toprule">
<p class="First"> </p>
<p>    QUADRAMET<span class="Sup">®</span><br>    1.0                                             mCi/kg<br>    N =                                             199</p>
</td>
</tr>
<tr>
<td>
<p class="First"> </p>
<p># Patients with Any Adverse Event</p>
</td>
<td>
<p class="First"> </p>
<p>    72                                         (80%)</p>
</td>
<td>
<p class="First"> </p>
<p>    169                                         (85%)</p>
</td>
</tr>
<tr>
<td>
<p class="First"> </p>
<p><span class="Bold">Body As A Whole</span></p>
</td>
<td>
<p class="First"> </p>
<p>    56                                         (62%)</p>
</td>
<td>
<p class="First"> </p>
<p>    100                                         (50%)</p>
</td>
</tr>
<tr>
<td>
<p class="First"> </p>
<p><span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">Pain</span> Flare Reaction</p>
</td>
<td>
<p class="First"> </p>
<p>    5                                         (5.6%)</p>
</td>
<td>
<p class="First"> </p>
<p>    14                                         (7.0%)</p>
</td>
</tr>
<tr>
<td>
<p class="First"> </p>
<p><span class="Bold">Cardiovascular</span></p>
</td>
<td>
<p class="First"> </p>
<p>    19                                         (21%)</p>
</td>
<td>
<p class="First"> </p>
<p>    32                                         (16%)</p>
</td>
</tr>
<tr>
<td>
<p class="First"> </p>
<p><span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">Arrhythmias</span></p>
</td>
<td>
<p class="First"> </p>
<p>    2                                         (2.2%)</p>
</td>
<td>
<p class="First"> </p>
<p>    10                                         (5.0%)</p>
</td>
</tr>
<tr>
<td>
<p class="First"> </p>
<p><span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">Chest Pain</span></p>
</td>
<td>
<p class="First"> </p>
<p>    4                                         (4.4%)</p>
</td>
<td>
<p class="First"> </p>
<p>    8                                         (4.0%)</p>
</td>
</tr>
<tr>
<td>
<p class="First"> </p>
<p><span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">Hypertension</span></p>
</td>
<td>
<p class="First"> </p>
<p>    0</p>
</td>
<td>
<p class="First"> </p>
<p>    6                                         (3.0%)</p>
</td>
</tr>
<tr>
<td>
<p class="First"> </p>
<p><span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">Hypotension</span></p>
</td>
<td>
<p class="First"> </p>
<p>    2                                         (2.2%)</p>
</td>
<td>
<p class="First"> </p>
<p>    4                                         (2.0%)</p>
</td>
</tr>
<tr>
<td>
<p class="First"> </p>
<p><span class="Bold">Digestive</span></p>
</td>
<td>
<p class="First"> </p>
<p>    44                                         (49%)</p>
</td>
<td>
<p class="First"> </p>
<p>    82                                         (41%)</p>
</td>
</tr>
<tr>
<td>
<p class="First"> </p>
<p><span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">Abdominal Pain</span></p>
</td>
<td>
<p class="First"> </p>
<p>    7                                         (7.8%)</p>
</td>
<td>
<p class="First"> </p>
<p>    12                                         (6.0%)</p>
</td>
</tr>
<tr>
<td>
<p class="First"> </p>
<p><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span></p>
</td>
<td>
<p class="First"> </p>
<p>    3                                         (3.3%)</p>
</td>
<td>
<p class="First"> </p>
<p>    12                                         (6.0%)</p>
</td>
</tr>
<tr>
<td>
<p class="First"> </p>
<p><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span> &amp;/or <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span></p>
</td>
<td>
<p class="First"> </p>
<p>    37                                             (41.1%)</p>
</td>
<td>
<p class="First"> </p>
<p>    65                                             (32.7%)</p>
</td>
</tr>
<tr>
<td>
<p class="First"> </p>
<p><span class="Bold">Hematologic &amp;                                                 Lymphatic</span></p>
</td>
<td>
<p class="First"> </p>
<p>    12                                         (13%)</p>
</td>
<td>
<p class="First"> </p>
<p>    54                                         (27%)</p>
</td>
</tr>
<tr>
<td>
<p class="First"> </p>
<p><span class="product-label-link" type="condition" conceptid="432585" conceptname="Blood coagulation disorder">Coagulation Disorder</span></p>
</td>
<td>
<p class="First"> </p>
<p>    0</p>
</td>
<td>
<p class="First"> </p>
<p>    3                                         (1.5%)</p>
</td>
</tr>
<tr>
<td>
<p class="First"> </p>
<p><span class="product-label-link" type="condition" conceptid="4013074" conceptname="Hemoglobin low">Hemoglobin Decreased</span></p>
</td>
<td>
<p class="First"> </p>
<p>    21                                             (23.3%)</p>
</td>
<td>
<p class="First"> </p>
<p>    81                                             (40.7%)</p>
</td>
</tr>
<tr>
<td>
<p class="First"> </p>
<p><span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">Leukopenia</span></p>
</td>
<td>
<p class="First"> </p>
<p>    6                                         (6.7%)</p>
</td>
<td>
<p class="First"> </p>
<p>    118(59.3%)</p>
</td>
</tr>
<tr>
<td>
<p class="First"> </p>
<p><span class="product-label-link" type="condition" conceptid="315085" conceptname="Lymphadenopathy">Lymphadenopathy</span></p>
</td>
<td>
<p class="First"> </p>
<p>    0</p>
</td>
<td>
<p class="First"> </p>
<p>    4                                         (2.0%)</p>
</td>
</tr>
<tr>
<td>
<p class="First"> </p>
<p><span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">Thrombocytopenia</span></p>
</td>
<td>
<p class="First"> </p>
<p>    8                                         (8.9%)</p>
</td>
<td>
<p class="First"> </p>
<p>    138(69.3%)</p>
</td>
</tr>
<tr>
<td>
<p class="First"> </p>
<p><span class="Bold">Any <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Bleeding</span> Manifestations*                                             </span></p>
</td>
<td>
<p class="First"> </p>
<p>    8                                         (8.9%)</p>
</td>
<td>
<p class="First"> </p>
<p>    32                                             (16.1%)</p>
</td>
</tr>
<tr>
<td>
<p class="First"> </p>
<p><span class="product-label-link" type="condition" conceptid="4118793" conceptname="Ecchymosis">Ecchymosis</span></p>
</td>
<td>
<p class="First"> </p>
<p>    1                                         (1.1%)</p>
</td>
<td>
<p class="First"> </p>
<p>    3                                         (3.0%)</p>
</td>
</tr>
<tr>
<td>
<p class="First"> </p>
<p><span class="product-label-link" type="condition" conceptid="318556" conceptname="Epistaxis">Epistaxis</span></p>
</td>
<td>
<p class="First"> </p>
<p>    1                                         (1.1%)</p>
</td>
<td>
<p class="First"> </p>
<p>    4                                         (2.0%)</p>
</td>
</tr>
<tr>
<td>
<p class="First"> </p>
<p><span class="product-label-link" type="condition" conceptid="75004" conceptname="Frank hematuria">Hematuria</span></p>
</td>
<td>
<p class="First"> </p>
<p>    3                                         (3.3%)</p>
</td>
<td>
<p class="First"> </p>
<p>    10                                         (5%)</p>
</td>
</tr>
<tr>
<td>
<p class="First"> </p>
<p><span class="Bold"><span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infection</span></span></p>
</td>
<td>
<p class="First"> </p>
<p>    10                                             (11.1%)</p>
</td>
<td>
<p class="First"> </p>
<p>    34                                             (17.1%)</p>
</td>
</tr>
<tr>
<td>
<p class="First"> </p>
<p><span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">Fever</span> and/or <span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">Chills</span></p>
</td>
<td>
<p class="First"> </p>
<p>    10                                             (11.1%)</p>
</td>
<td>
<p class="First"> </p>
<p>    17                                         (8.5%)</p>
</td>
</tr>
<tr>
<td>
<p class="First"> </p>
<p><span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infection</span>, Not Specified</p>
</td>
<td>
<p class="First"> </p>
<p>    4                                         (4.4%)</p>
</td>
<td>
<p class="First"> </p>
<p>    14                                         (7.0%)</p>
</td>
</tr>
<tr>
<td>
<p class="First"> </p>
<p><span class="product-label-link" type="condition" conceptid="29735" conceptname="Candidiasis of mouth">Oral Moniliasis</span></p>
</td>
<td>
<p class="First"> </p>
<p>    1                                         (1.1%)</p>
</td>
<td>
<p class="First"> </p>
<p>    4                                         (2.0%)</p>
</td>
</tr>
<tr>
<td>
<p class="First"> </p>
<p><span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">Pneumonia</span></p>
</td>
<td>
<p class="First"> </p>
<p>    1                                         (1.1%)</p>
</td>
<td>
<p class="First"> </p>
<p>    3                                         (1.5%)</p>
</td>
</tr>
<tr>
<td>
<p class="First"> </p>
<p><span class="Bold">Musculoskeletal</span></p>
</td>
<td>
<p class="First"> </p>
<p>    28                                         (31%)</p>
</td>
<td>
<p class="First"> </p>
<p>    55                                         (27%)</p>
</td>
</tr>
<tr>
<td>
<p class="First"> </p>
<p><span class="product-label-link" type="condition" conceptid="79908" conceptname="Muscle weakness">Myasthenia</span></p>
</td>
<td>
<p class="First"> </p>
<p>    8                                         (8.9%)</p>
</td>
<td>
<p class="First"> </p>
<p>    13                                         (6.5%)</p>
</td>
</tr>
<tr>
<td>
<p class="First"> </p>
<p>Pathologic <span class="product-label-link" type="condition" conceptid="75053" conceptname="Fracture of bone">Fracture</span></p>
</td>
<td>
<p class="First"> </p>
<p>    2                                         (2.2%)</p>
</td>
<td>
<p class="First"> </p>
<p>    5                                         (2.5%)</p>
</td>
</tr>
<tr>
<td>
<p class="First"> </p>
<p><span class="Bold">Nervous</span></p>
</td>
<td>
<p class="First"> </p>
<p>    39                                         (43%)</p>
</td>
<td>
<p class="First"> </p>
<p>    59                                         (30%)</p>
</td>
</tr>
<tr>
<td>
<p class="First"> </p>
<p><span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span></p>
</td>
<td>
<p class="First"> </p>
<p>    1                                         (1.1%)</p>
</td>
<td>
<p class="First"> </p>
<p>    8                                         (4.0%)</p>
</td>
</tr>
<tr>
<td>
<p class="First"> </p>
<p><span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">Paresthesia</span></p>
</td>
<td>
<p class="First"> </p>
<p>    7                                         (7.8%)</p>
</td>
<td>
<p class="First"> </p>
<p>    4                                         (2.0%)</p>
</td>
</tr>
<tr>
<td>
<p class="First"> </p>
<p><span class="product-label-link" type="condition" conceptid="4322945" conceptname="Spinal cord compression">Spinal Cord Compression</span></p>
</td>
<td>
<p class="First"> </p>
<p>    5                                         (5.5%)</p>
</td>
<td>
<p class="First"> </p>
<p>    13                                         (6.5%)</p>
</td>
</tr>
<tr>
<td>
<p class="First"> </p>
<p><span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">Cerebrovascular Accident</span>/<span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">Stroke</span></p>
</td>
<td>
<p class="First"> </p>
<p>    0</p>
</td>
<td>
<p class="First"> </p>
<p>    2                                         (1.0%)</p>
</td>
</tr>
<tr>
<td>
<p class="First"> </p>
<p><span class="Bold">Respiratory</span></p>
</td>
<td>
<p class="First"> </p>
<p>    24                                         (27%)</p>
</td>
<td>
<p class="First"> </p>
<p>    35                                         (18%)</p>
</td>
</tr>
<tr>
<td>
<p class="First"> </p>
<p><span class="product-label-link" type="condition" conceptid="256451" conceptname="Bronchitis">Bronchitis</span>/<span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">Cough Increased</span></p>
</td>
<td>
<p class="First"> </p>
<p>    2                                         (2.2%)</p>
</td>
<td>
<p class="First"> </p>
<p>    8                                         (4.0%)</p>
</td>
</tr>
<tr>
<td>
<p class="First"> </p>
<p><span class="Bold">Special Senses</span></p>
</td>
<td>
<p class="First"> </p>
<p>    11                                         (12%)</p>
</td>
<td>
<p class="First"> </p>
<p>    11                                         (6%)</p>
</td>
</tr>
<tr>
<td>
<p class="First"> </p>
<p><span class="Bold">Skin &amp;                                             Appendages</span></p>
</td>
<td>
<p class="First"> </p>
<p>    17                                             (19%)    </p>
</td>
<td>
<p class="First"> </p>
<p>    13                                         (7%)</p>
</td>
</tr>
<tr>
<td>
<p class="First"> </p>
<p><span class="product-label-link" type="condition" conceptid="4047773" conceptname="Purpura">Purpura</span></p>
</td>
<td>
<p class="First"> </p>
<p>    0</p>
</td>
<td>
<p class="First"> </p>
<p>    2                                         (1%)</p>
</td>
</tr>
<tr class="Last">
<td class="Botrule">
<p class="First"> </p>
<p><span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rash</span></p>
</td>
<td class="Botrule">
<p class="First"> </p>
<p>    2                                         (2.2%)</p>
</td>
<td class="Botrule">
<p class="First"> </p>
<p>    2                                         (1%)</p>
</td>
</tr>
</tbody>
</table>
<dl>
<dt>•</dt>
<dd>*Includes <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">hemorrhage</span> (gastrointestinal, ocular) reported in                                 &lt;1%. </dd>
</dl>
<p>In an additional 200 patients who received                                 QUADRAMET<span class="Sup">®</span> in uncontrolled clinical trials,                             adverse events that were reported at a rate of ≥ 1.0%                             were similar except for 9 (4.5%) patients who had <span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">agranulocytosis</span>. Other                             selected adverse events that were reported in &lt;1% of the patients                             who received QUADRAMET<span class="Sup">®</span> 1.0 mCi/kg in any clinical                             trial include: <span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">alopecia</span>, angina, <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span>, sinus                             <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span>, and vasodilation.</p>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="LINK_ec788889-1f9a-4fba-80f4-6627286a496a"></a><a name="section-9"></a><p></p>
<h1>OVERDOSAGE</h1>
<p class="First">Overdosage with QUADRAMET<span class="Sup">®</span> has not been                             reported. An antidote for QUADRAMET<span class="Sup">®</span> overdosage is                             not known. The anticipated complications of overdosage would likely be                             secondary to bone marrow suppression from the radioactivity of                             <span class="Sup">153</span>Sm, or secondary to <span class="product-label-link" type="condition" conceptid="435510" conceptname="Hypocalcemia">hypocalcemia</span> and <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">cardiac arrhythmias</span>                             related to the EDTMP.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="LINK_3ee7b7bd-d2d0-44f8-911d-5df0d54531d0"></a><a name="section-10"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION</h1>
<p class="First">The recommended dose of QUADRAMET<span class="Sup">®</span> is 1.0                             mCi/kg, administered intravenously over a period of one minute through a                             secure in-dwelling catheter and followed with a saline flush. Dose                             adjustment in patients at the extremes of weight have not been studied.                             Caution should be exercised when determining the dose in very thin or                             very obese patients.</p>
<p>The dose should be measured by a suitable radioactivity                             calibration system, such as a radioisotope dose calibrator, immediately                             before administration.</p>
<p>The dose of radioactivity to be administered and the patient                             should be verified before administering QUADRAMET<span class="Sup">®</span>.                             Patients should not be released until their radioactivity levels and                             exposure rates comply with federal and local regulations.</p>
<p>The patient should ingest (or receive by i.v. administration) a                             minimum of 500 mL (2 cups) of fluids prior to injection and should void                             as often as possible after injection to minimize <span class="product-label-link" type="condition" conceptid="438630" conceptname="Exposure to radiation">radiation exposure</span> to                             the bladder.</p>
<p>Parenteral drug products should be inspected visually for                             particulate matter and discoloration prior to administration whenever                             solution and container permit. The solution should not be used if it is                             cloudy or if it contains particulate matter.</p>
<p>QUADRAMET<span class="Sup">®</span> contains calcium and may be                             incompatible with solutions that contain molecules that can complex with                             and form calcium precipitates.</p>
<p>QUADRAMET<span class="Sup">®</span> should not be diluted or mixed                             with other solutions.</p>
<p>Thaw at room temperature before administration and use within 8                             hours of thawing.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_d99d9036-bb2e-4d42-ba1d-0aa73e08fd90"></a><a name="section-10.1"></a><p></p>
<h2>Radiation Dosimetry</h2>
<p class="First">The estimated absorbed radiation doses to an average 70                                     kg adult patient from an i.v. injection of                                         QUADRAMET<span class="Sup">®</span> are shown in Table 7. The                                     dosimetry estimates were based on clinical biodistribution                                     studies using methods developed for radiation dose calculations                                     by the Medical Internal Radiation Dose (MIRD) Committee of the                                     Society of Nuclear Medicine.</p>
<p><span class="product-label-link" type="condition" conceptid="438630" conceptname="Exposure to radiation">Radiation exposure</span> is based on a urinary voiding interval                                     of 4.8 hours. Radiation dose estimates for bone and marrow                                     assume that radioactivity is deposited on bone surfaces, as                                     noted in autoradiograms of biopsy bone samples in 7 patients who                                     received QUADRAMET<span class="Sup">®</span>. Although electron                                     emissions from <span class="Sup">153</span>Sm are abundant, with energies up                                     to 810 keV, rapid blood clearance of                                     QUADRAMET<span class="Sup">®</span> and low energy and abundant                                     photon emissions generally result in low radiation doses to                                     those parts of the body where the complex does not localize.</p>
<p>When blastic osseous lesions are present, significantly                                     enhanced localization of the radiopharmaceutical will occur,                                     with correspondingly higher doses to the lesions compared with                                     normal bones and other organs. (See <a href="#_Ref">Clinical                                         Pharmacology</a>, <a href="#_Ref">Skeletal                                     Uptake</a> and <a href="#_Ref">Pharmacodynamics</a> Sections).</p>
<a name="_RefID0ELCAG"></a><table>
<caption><span>TABLE 7 RADIATION ABSORBED DOSES </span></caption>
<col width="33%">
<col width="33%">
<col width="33%">
<tbody class="Headless">
<tr class="First"><td class="Toprule" align="center" colspan="3">
<p class="First"> </p>
<p><span class="Bold">70 kg ADULT</span></p>
</td></tr>
<tr>
<td>
<p class="First"> </p>
<p><span class="Bold">Target Organ</span></p>
</td>
<td>
<p class="First"> </p>
<p><span class="Bold">    Rad/</span><span class="Bold">mCi</span></p>
</td>
<td>
<p class="First"> </p>
<p><span class="Bold">mGy</span><span class="Bold">/</span><span class="Bold">MBq</span></p>
</td>
</tr>
<tr>
<td>
<p class="First"> </p>
<p>Bone Surfaces</p>
</td>
<td>
<p class="First"> </p>
<p>    25.0</p>
</td>
<td>
<p class="First"> </p>
<p>    6.76</p>
</td>
</tr>
<tr>
<td>
<p class="First"> </p>
<p>Red Marrow</p>
</td>
<td>
<p class="First"> </p>
<p>    5.70</p>
</td>
<td>
<p class="First"> </p>
<p>    1.54</p>
</td>
</tr>
<tr>
<td>
<p class="First"> </p>
<p>Urinary Bladder Wall</p>
</td>
<td>
<p class="First"> </p>
<p>    3.60</p>
</td>
<td>
<p class="First"> </p>
<p>    0.097</p>
</td>
</tr>
<tr>
<td>
<p class="First"> </p>
<p>Kidneys</p>
</td>
<td>
<p class="First"> </p>
<p>    0.065</p>
</td>
<td>
<p class="First"> </p>
<p>    0.018</p>
</td>
</tr>
<tr>
<td>
<p class="First"> </p>
<p>Whole Body</p>
</td>
<td>
<p class="First"> </p>
<p>    0.040</p>
</td>
<td>
<p class="First"> </p>
<p>    0.011</p>
</td>
</tr>
<tr>
<td>
<p class="First"> </p>
<p>Lower large intestine</p>
</td>
<td>
<p class="First"> </p>
<p>    0.037</p>
</td>
<td>
<p class="First"> </p>
<p>    0.010</p>
</td>
</tr>
<tr>
<td>
<p class="First"> </p>
<p>Ovaries</p>
</td>
<td>
<p class="First"> </p>
<p>    0.032</p>
</td>
<td>
<p class="First"> </p>
<p>    0.0086</p>
</td>
</tr>
<tr>
<td>
<p class="First"> </p>
<p>Muscle</p>
</td>
<td>
<p class="First"> </p>
<p>    0.028</p>
</td>
<td>
<p class="First"> </p>
<p>    0.0076</p>
</td>
</tr>
<tr>
<td>
<p class="First"> </p>
<p>Small Intestine</p>
</td>
<td>
<p class="First"> </p>
<p>    0.023</p>
</td>
<td>
<p class="First"> </p>
<p>    0.0062</p>
</td>
</tr>
<tr>
<td>
<p class="First"> </p>
<p>Upper Large Intestine</p>
</td>
<td>
<p class="First"> </p>
<p>    0.020</p>
</td>
<td>
<p class="First"> </p>
<p>    0.0054</p>
</td>
</tr>
<tr>
<td>
<p class="First"> </p>
<p>Testes</p>
</td>
<td>
<p class="First"> </p>
<p>    0.020</p>
</td>
<td>
<p class="First"> </p>
<p>    0.0054</p>
</td>
</tr>
<tr>
<td>
<p class="First"> </p>
<p>Liver</p>
</td>
<td>
<p class="First"> </p>
<p>    0.019</p>
</td>
<td>
<p class="First"> </p>
<p>    0.0051</p>
</td>
</tr>
<tr>
<td>
<p class="First"> </p>
<p>Spleen</p>
</td>
<td>
<p class="First"> </p>
<p>    0.018</p>
</td>
<td>
<p class="First"> </p>
<p>    0.0049</p>
</td>
</tr>
<tr class="Last">
<td class="Botrule">
<p class="First"> </p>
<p>Stomach</p>
</td>
<td class="Botrule">
<p class="First"> </p>
<p>    0.015</p>
</td>
<td class="Botrule">
<p class="First"> </p>
<p>    0.0041</p>
</td>
</tr>
</tbody>
</table>
</div>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="LINK_655036ea-90f4-43a6-8fc7-c01f75896821"></a><a name="section-11"></a><p></p>
<h1>HOW SUPPLIED</h1>
<p class="First">QUADRAMET<span class="Sup">®</span> is supplied frozen in a                             single-dose 10 mL glass vial containing 1850 ± 185 MBq/mL (50                             ± 5 mCi/mL) of samarium-153, at calibration.</p>
<p>QUADRAMET<span class="Sup">®</span> is available in the following                             size:</p>
<p>NDC# 11994-016-01 3mL fill size with total activity of 5550 MBq                             (150mCi).</p>
<p>The vial is shipped in a lead shield; a package insert is                             included.</p>
<p>The drug product expires 56 hours after the time of calibration                             noted on the label, or 8 hours after thawing, whichever is earlier.</p>
<p><span class="Bold">STORAGE:</span> Store frozen at                             -10° to -20°C in a lead shielded container.</p>
<p>Storage and disposal of QUADRAMET<span class="Sup">®</span> should be                             controlled in a manner that complies with the appropriate regulations of                             the government agency authorized to license the use of this                             radionuclide. </p>
<p>This radioactive drug is approved for distribution to persons                             licensed pursuant to the Code of Massachusetts Regulations 105 CMR                             120.500 for the uses listed in 105 CMR 120.537 or under equivalent                             licenses of the U.S. Nuclear Regulatory Commission, an Agreement State                             or a Licensing State.</p>
<p>THIS PRODUCT<br>INFORMATION ISSUED December 2013.</p>
<p><span class="Bold">Manufactured by:</span></p>
<p>Lantheus Medical Imaging<br>N. Billerica, MA 01862</p>
<p>For Ordering Tel: Toll Free: 800-299-3431<br>All other business: 800-362-2668<br>For Massachusetts and International: 978-667-9531</p>
<p>Printed in U.S.A.</p>
<p>513145-1213</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="LINK_07fff120-8a71-4f0b-9fbb-60110085790d"></a><a name="section-12"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL - 3 mL Vial Label</h1>
<p class="First"><span class="Bold">Quadramet</span><span class="Sup">® </span>Samarium Sm153 Lexidronam Injection</p>
<p>Sterile, Non-pyrogenic, Intravenous Injection<br><span class="Bold">Contents &amp; Assay: </span>35 mg/mL EDTMP•H<span class="Sub">2</span>O; 5.3 mg/mL<br>Ca[as Ca(OH)<span class="Sub">2</span>]; 14.1 mg/mL Na[as NaOH]; 5-46 µg Samarium;<br>1850 ± 185 MBq/mL (50 ± 5 mCi/mL) of Samarium–153<br>at calibration. Store frozen at -10° to -20°C (14° to -4° F).<br>Thaw at room temperature before administration<br>and use within 8 hours of thawing. <span class="Bold">Rx only</span><br>See Package Insert for dosing information.<br><span class="Bold">This Product Contains Dry Natural Rubber.</span></p>
<p><span class="Bold">Caution: Radioactive Material</span></p>
<p>Manufactured Under License from EUSA Pharma (USA), Inc.</p>
<p>Mfd by:<br><span class="Bold">Lantheus <br>Medical Imaging<span class="Sup">®</span></span><br>N. Billerica, MA 01862</p>
<p>515127-1213</p>
<div class="Figure"><img alt="Principal Display Panel - 3 mL Vial Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=61e84808-0999-4923-910c-2a480d5f971a&amp;name=quadramet-02.jpg"></div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>QUADRAMET 		
					</strong><br><span class="contentTableReg">samarium sm 153 lexidronam injection, solution</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:11994-016</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">INTRAVENOUS</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>SAMARIUM SM-153 LEXIDRONAM PENTASODIUM</strong> (SAMARIUM SM-153) </td>
<td class="formItem">SAMARIUM SM-153</td>
<td class="formItem">50 mCi  in 1 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>LEXIDRONAM</strong></td>
<td class="formItem">35 mg  in 1 mL</td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CALCIUM HYDROXIDE</strong></td>
<td class="formItem">5.3 mg  in 1 mL</td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SODIUM HYDROXIDE</strong></td>
<td class="formItem">14 mg  in 1 mL</td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:11994-016-01</td>
<td class="formItem">3 mL in 1 VIAL, SINGLE-DOSE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA020570</td>
<td class="formItem">05/19/1997</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Lantheus Medical Imaging, Inc.
							(176786812)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Lantheus Medical Imaging, Inc.</td>
<td class="formItem"></td>
<td class="formItem">176786812</td>
<td class="formItem">MANUFACTURE(11994-016), PACK(11994-016), LABEL(11994-016)</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 12/2013<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>22b7d40e-5f65-4541-8cce-7d600738bb9e</div>
<div>Set id: 61e84808-0999-4923-910c-2a480d5f971a</div>
<div>Version: 1</div>
<div>Effective Time: 20131218</div>
</div>
</div> <div class="DistributorName">Lantheus Medical Imaging, Inc.</div></p>
</body></html>
